January 20th, 2021
In the context of the expansion of our Rare Diseases Division, Varifarma is highly pleased to announce that JANVAX® will be joining our portfolio of drugs available for the treatment of patients with Rheumatoid Arthritis and Psoriatic Arthritis. JANVAX® (tofacitinib) reduces disease progression* and improves patients’ quality of life (QoL), while reducing joint pain, damage and inflammation*.
JANVAX® Tofacitinib - In Rheumatoid Arthritis, free range of motion
JANVAX® is a selective Janus Kinase 1 and 3 inhibitor.
Reduces disease progression (2)
Improves patients’ QoL,(2) while reducing joint pain, damage and inflammation
In ORAL Strategy, Tofacitinib 5 mg BID plus methotrexate showed non-inferiority versus Adalimumab and methotrexate for the treatment of patients with RA and inadequate response to methotrexate.
JANVAX® is approved by the Ministry of Health. Certificate No 59257. July 2020.
References:
1. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367: 495-507.
2. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014; 370: 2377-86